Author + information
- Christopher M. Rembold, MD⁎ ()
- ↵⁎Cardiovascular Division, University of Virginia Health System, Box 800146 Health System, Charlottesville, Virginia 22908
I disagree with the data analysis in the recently published article in the Journal suggesting an association between lower statin-induced low-density lipoprotein (LDL) levels and increased incidence of cancer (1). My analysis of the 8 larger and longer trials (>3 years and >1,000 patients) suggests a clear association between increasing age and increased incidence of cancer (Fig. 1) (r2 = 0.77, p = 0.004, regression not corrected for study size). Age is a known and biologically plausible risk factor for cancer. Multivariate linear regression resulted in the following model:
The overall model was significant with r2 = 0.83 and p = 0.013. The multivariate p value for the coefficient of age (p = 0.055) was nearly statistically significant and lower than the multivariate p value for the coefficient of LDL on treatment (p = 0.26). This model suggests that age is more predictive of cancer incidence than LDL on treatment. Based on this analysis, we should reconsider the assertion that statin-induced lowering of LDL is associated with increased cancer incidence.
Please note: Dr. Rembold has received honoraria for lectures on dyslipidemia from Kos Pharmaceuticals, Abbott, AstraZeneca, Merck, Schering-Plough, and Pfizer.
- American College of Cardiology Foundation